2026年2月6日，港股创新药企云顶新耀(01952)宣布，其自身免疫性疾病领域的核心产品维适平 (精氨酸 艾曲莫德片, VELSIPITY )获得中国国家药品监督管理局(NMPA)批准上市，用于治疗对传统治疗或生物 制剂应答不充分、失应答或不耐受的中度至重度活动性溃疡性结肠炎(UC)成人患者。 国际权威指南一线推荐 成熟商业化平台将加速维适平 市场落地 作为新一代高选择性S1P受体调节剂，维适平 每日一次口服，可实现快速起效和强效深度黏膜愈合，并 具有良好的安全性特征，具备最佳药物(best-in-disease)潜质，为成人溃疡性结肠炎患者提供新的一线治 疗选择，其商业化前景获业内广泛看好。据预测，其销售峰值或达50亿元，将成为云顶新耀继肾病领域 耐赋康 后的又一核心单品，此举也预示着其商业化版图有望迎来新一轮高速增长。 云顶新耀首席执行官罗永庆对此表示，此次维适平 在中国的获批，填补了中重度溃疡性结肠炎治疗领 域的重要空白，并为以深度黏膜愈合为目标的创新口服治疗提供了新的选择。公司将加快推进维适平 的商业化进程，并积极推动纳入国家医保目录，持续提升创新疗法在中国的可及性和可负担性，让更多 患者受益。 维 ...

Core Insights - The company, CloudTop New Horizon, has established a solid foundation over the past eight years through license-in strategies and aims to become a leading global biopharmaceutical company by 2030 with a revenue target of over 15 billion RMB and more than 20 commercialized products [1][2][10] Group 1: Strategic Development - The 2030 development strategy focuses on a dual approach of business development (BD) cooperation and independent research and development, targeting a revenue of over 15 billion RMB and over 20 commercialized products by 2030 [1][2][10] - The company plans to introduce 3-5 late-stage blockbuster products annually over the next five years, enhancing its product pipeline [3][10] - The strategic partnerships with Haisen Biopharmaceuticals will provide commercialization services for six approved products, generating service fees based on quarterly net sales [3][4] Group 2: Product Pipeline and Market Focus - The company will focus on key therapeutic areas such as nephrology, autoimmune diseases, critical care, cardiovascular, and ophthalmology, aiming to create a high-value product portfolio by 2030 [2][10] - The revenue from existing pipelines is projected to be around 9 billion RMB, with new pipeline sales expected to contribute approximately 6 billion RMB [2] - The company has successfully commercialized the drug Nefukang, which has rapidly gained market traction, demonstrating its commercial capabilities [7][10] Group 3: Research and Development - CloudTop New Horizon is advancing its self-developed mRNA platforms, including CAR-T and tumor vaccine platforms, with ongoing clinical trials [8][9] - The company plans to expand its R&D capabilities by introducing and incubating potential platforms, aiming to strengthen its core therapeutic areas [9][10] - The new reversible BTK inhibitor EVER001 has shown promising clinical data, indicating a steady global R&D progress [9] Group 4: Commercialization Strategy - The company is leveraging its integrated commercialization platform, which combines scientific and market insights, to enhance its operational efficiency and productivity [4][8] - The collaboration with Haisen Biopharmaceuticals exemplifies the company's ability to extend its commercialization capabilities to mature products [8] - The company aims to transition from a biotech firm to a comprehensive biopharmaceutical company with global competitiveness, reflecting a broader trend in the Chinese innovative drug industry [8][10]

Core Insights - WeRide, known as the "first Robotaxi stock globally," successfully completed its dual listing on the Hong Kong Stock Exchange, filling a gap in the market for Robotaxi stocks in Hong Kong [1][4] - The company reported strong financial results for Q3 2025, with revenue reaching 171 million yuan, a year-on-year increase of 144.3%, and a significant growth in Robotaxi business revenue [3][5] - The company has established a robust presence in the autonomous driving market, with over 1,600 autonomous vehicles globally, including nearly 750 Robotaxis [3][8] Financial Performance - Q3 2025 revenue was 171 million yuan, marking a 144.3% increase year-on-year, the largest quarterly growth since the company's inception [3] - Robotaxi business revenue reached 35.3 million yuan, a staggering 761.0% increase year-on-year [3] - Gross profit was 56.3 million yuan, up 1,123.9% year-on-year, with a gross margin of 32.9%, an increase of 26.4 percentage points year-on-year [3] Market Position and Strategy - WeRide has secured a unique position as the only technology company with autonomous driving licenses in eight countries, showcasing significant first-mover advantages [8][14] - The company has established partnerships with major players like Uber and Grab, enhancing its market reach and operational capabilities [15] - WeRide's strategic focus on commercializing its autonomous driving technology across various applications, including Robotaxi, Robobus, and Robovan, demonstrates its commitment to diversifying revenue streams [5][17] Technological Advancements - The WeRide One autonomous driving platform and WeRide GENESIS simulation engine create high barriers to entry, ensuring reliability and safety in autonomous driving systems [6][9] - The company has maintained a leading position in safety and reliability, with over 55 million kilometers of public road testing and no regulatory penalties due to system failures [11] Global Expansion - WeRide has expanded its operations to 30 cities across 11 countries, transitioning from pilot operations to large-scale deployment [8][17] - The company has recently received approval for fully autonomous Robotaxi operations in Abu Dhabi, marking a significant milestone in its global expansion strategy [15] - The Robotaxi service is set to launch in Singapore, further solidifying WeRide's presence in key international markets [12][14] Future Outlook - The global Robotaxi service market is projected to reach $66.6 billion by 2030, with a compound annual growth rate of 196% from 2025 to 2030, positioning WeRide to benefit from significant market growth [16] - The company is expected to demonstrate the feasibility and scalability of its autonomous driving business model, paving the way for future financial performance improvements [17][18]